BMS, Biogen deal

Bristol-Myers granted Biogen exclusive rights to BMS-986168. The mAb targeting microtubule-associated protein tau

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE